Brief: Vallon Pharmaceuticals Reports Additional Pharmacokinetic And Pharmacodynamic Data From SEAL Study Of ADAIR
12/05/2022 13:40
May 12 (Reuters) - Vallon Pharmaceuticals Inc VLON.O :
* VALLON PHARMACEUTICALS REPORTS ADDITIONAL PHARMACOKINETIC
AND
PHARMACODYNAMIC DATA FROM SEAL STUDY OF ADAIR
* VALLON PHARMACEUTICALS INC - IN APRIL 2022, VALLON
COMMENCED A
REVIEW OF STRATEGIC ALTERNATIVES FOR COMPANY
Source text for Eikon: ID:nGNX8dyyqt
Further company coverage: VLON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027